Metraipolis › archive › dc_bc6ae2e844e5

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human… — Europe PMC PMID:40260627

Source
Europe PMC (en)
Original
https://europepmc.org/article/MED/40260627
DOI
10.1158/1078-0432.ccr-25-0206
License (as archived)
solo-consultazione
Archived
2026-11-08T21:20:58.891Z
SHA-256 of the archived text
45f775f289df5b7387ead475f15cc3f6cb564d3de23cf8abb2195b79e93ac517
Stable URL of this page
https://metraipolis.com/documento/dc_bc6ae2e844e5

How to cite

Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human… — Europe PMC PMID:40260627 — Europe PMC (en), https://europepmc.org/article/MED/40260627 (solo-consultazione); archived copy: https://metraipolis.com/documento/dc_bc6ae2e844e5 (Metraipolis archive dc_bc6ae2e844e5, sha256 45f775f289df5b7387ead475f15cc3f6cb564d3de23cf8abb2195b79e93ac517)
BibTeX
@misc{dcbc6ae2e844e5,
  title = {Izalontamab (SI-B001), a Novel EGFRxHER3 Bispecific Antibody in Patients with Locally Advanced or Metastatic Epithelial Tumor: Results from First-in-Human… — Europe PMC PMID:40260627},
  howpublished = {Europe PMC (en)},
  url = {https://europepmc.org/article/MED/40260627},
  note = {License solo-consultazione; archived copy https://metraipolis.com/documento/dc_bc6ae2e844e5; sha256 45f775f289df5b7387ead475f15cc3f6cb564d3de23cf8abb2195b79e93ac517},
  year = {2026}
}

Archived text

The text is not reproduced here: the archive holds it as solo-consultazione (consultation only, no republication). Read it at the original source: https://europepmc.org/article/MED/40260627. Agents can read the archived copy with the MCP tool read_document.